title: Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.
abstract: We report the clinical features and outcome of 22 TLS-ERG+leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with and without EMD was 75% and 83.3% (p = .017). 11/20 AML patients received allogeneic hematopoietic stem cell transplantation (HCT). The 1-year overall survival (OS) in non-HCT and HCT group was 62.5% and 90% (p = .026), but the 6-month LFS in non-HCT and HCT group was 55.6% and 100% (p = .192). The 6-month LFS of patients with complete remission (CR) before HCT versus those with no response (NR) was 67.5% and 0, respectively (p = .034). In conclusion, the leukemia burden before HCT and EMD had negative impact on the outcome of TLS-ERG patients; HCT could prolong OS, but could not overcome the poor prognostic impact of TLS-ERG.
authors.affiliation: a Department of Hematology , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Jing
authors.initials: J
authors.lastname: Pan
authors.affiliation: b Pathology & Laboratory Medicine Division , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: c Department of Bone Marrow Transplantation , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Zhao
authors.affiliation: a Department of Hematology , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Jun-Fang
authors.initials: JF
authors.lastname: Yang
authors.affiliation: c Department of Bone Marrow Transplantation , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Zhang
authors.affiliation: b Pathology & Laboratory Medicine Division , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Hong-Xing
authors.initials: HX
authors.lastname: Liu
authors.affiliation: c Department of Bone Marrow Transplantation , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Tong
authors.initials: T
authors.lastname: Wu
authors.affiliation: a Department of Hematology , Hebei Yanda Lu Daopei Hospital , Langfang , China.
authors.forename: Chun-Rong
authors.initials: CR
authors.lastname: Tong
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000379:methods; D018450:Disease Progression; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D007938:Leukemia / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D008297:Male; D009154:Mutation; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011379:Prognosis; D034702:RNA-Binding Protein FUS / Q000235:genetics*; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D015514:Oncogene Proteins, Fusion; D034702:RNA-Binding Protein FUS; C107302:TLS-ERG fusion protein, human
keywords: Leukemia; TLS-ERG; allogeneic hematopoietic stem cell transplantation; extramedullary disease; prognosis